ArticlesThree-Year Follow-up of Biomicroscopy Signs and Refractive Status in Patients Wearing Lotrafilcon A LensesLong, Bill B.S., M.B.A.; Malet, Florence M.D.; Lejeune, Marie M.D.; George-Vicariot, Marie-Noëlle M.D.; Pagot, Roland M.D.; Peyre, Catherine M.D.; Subirana, Xavier M.D.Author Information From CIBA Vision Corporation (B.L.), Duluth, GA; Hôpital Pelegrin (F.M.), Bordeaux Cedex, France; Lyon (M.L.), France; Coueron (M-N.G-V.), France; Strasbourg (R.P.), France; Paris (C.P.), France; Toulouse (X.S.), France. This study was funded and designed by CIBA Vision Corporation, a Novartis company. Address correspondence and reprint requests to Bill Long, CIBA Vision Corporation, Global Clinical Affairs, 11460 John’s Creek Parkway, Duluth, GA 30097; e-mail: [email protected]. Accepted February 16, 2005. Eye & Contact Lens: Science & Clinical Practice: November 2005 - Volume 31 - Issue 6 - p 263-267 doi: 10.1097/01.ICL.0000162744.67780.1F Buy Metrics Abstract Purpose. To report the wearer experience, biomicroscopy signs, and stability of refractive error after 3 years’ use of lotrafilcon A lenses. Methods. Seventy-four subjects from a multicenter clinical trial with lotrafilcon A lenses were queried on aspects of lens wear. Biomicroscopy signs and refractive error were compared to baseline measurements. Results. A total of 66% of subjects reported continuing to wear lotrafilcon A lenses, usually for more than 21 nights, with high satisfaction. Signs of limbal, palpebral, and bulbar redness improved significantly. Average refractive error remained stable. Conclusions. Long-term use of lotrafilcon A lenses resulted in high wearer satisfaction, reduction of ocular redness, and stable refractive error. © 2005 Lippincott Williams & Wilkins, Inc.